COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series

Review Neurosciences

Drugs Used in the Treatment of Multiple Sclerosis During COVID-19 Pandemic: A Critical Viewpoint

Marika Alborghetti et al.

Summary: This article discusses the impact of different drugs approved for the treatment of multiple sclerosis (MS) on COVID-19 infection. Interferon (IFN)-beta 1a and -1b may have a protective effect in the early stages of COVID-19, but may be detrimental during the hyperinflammation stage. Glatiramer acetate and its analogues may be considered safe, while teriflunomide and dimethyl fumarate may have antiviral activity and protective effects. Caution is needed for the use of other treatment options.

CURRENT NEUROPHARMACOLOGY (2022)

添加到收藏夹

Review Virology

Impact of disease-modifying drugs on the severity of COVID-19 infection in multiple sclerosis patients

Sahar Rostami Mansoor et al.

Summary: Neurological manifestations can occur in severe cases of COVID-19, leading neurologists to pay special attention to patients with neurological disorders like MS. Administering proper DMTs is critical for MS patients during the pandemic as it can help reduce immune responses.

JOURNAL OF MEDICAL VIROLOGY (2021)

添加到收藏夹

Article Clinical Neurology

Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

Maria P. Sormani et al.

Summary: This study assessed the impact of immunosuppressive and immunomodulatory therapies on the severity of COVID-19 in people with multiple sclerosis. Therapy with an anti-CD20 agent and recent use of methylprednisolone were associated with increased risk of severe COVID-19.

ANNALS OF NEUROLOGY (2021)

添加到收藏夹

Review Clinical Neurology

COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review

Fioravante Capone et al.

Summary: The study described a case of a MS patient treated with teriflunomide who developed a mild form of SARS-CoV-2 infection, along with a literature review on existing cases. Most patients fared well with the treatment. The use of teriflunomide in COVID-19 cases provides valuable insights.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology

COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America COVID-19 in MS and NMOSD patients in LATAM

Ricardo Alonso et al.

Summary: This study aimed to investigate the clinical characteristics and outcomes of MS and NMOSD patients infected with COVID-19 in Latin America. The research found that age and disease duration were associated with hospitalization and ICU admission requirement in MS patients, while age, disease duration, and EDSS score were associated with hospitalization and ICU admission in NMOSD patients.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Review Clinical Neurology

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

Maryam Sharifian-Dorche et al.

Summary: This study reviews the impact of COVID-19 on patients with demyelinating diseases of the central nervous system like Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD), finding no clear relationship between disease-modifying therapies (DMT) use and the course of COVID-19. Risk factors for severe COVID-19 included age, higher EDSS scores, cardiac comorbidities, and obesity. Despite infection risks, most patients chose to continue DMT due to concerns about relapse or worsened MS symptoms, with some immune response attenuation seen in patients on specific medications post-infection.

MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology